Effectiveness of staged combined pharmacolaser therap and condyloma prevention

Purpose: To assess therapeutic antirecurrent effects of a staged combined laser technique as well as a combined antiviral therapy in the comprehensive treatment of anogenital condylomas (AGC) in children and teenagers. Materials and methods. Clinical and laboratory findings were used for analyzing results of a new laser technology applied in 135 children and adolescents aged from 3 months till 18 years with AGC which lasted up to 4 years and, the previous treatment with traditional therapy was ineffective. Patients were divided into 3 groups: group I (30 patients) who had laser destruction (LD); group II (30 patients) - LD with low-level laser therapy (LLLT) to follow; group III (75 patients) - combined therapy with LD + LLLT + antiviral drugs. In the control group, there were 30 healthy children. The study design included: examination - for one week; therapy - for 4-6 weeks (from 1 to 4-6 weeks); follow-up period and evaluation of long-term outcomes in 27 and 54 weeks. Results. A sharp decrease of AGC recurrences in patients from group III has proved a high efficiency of the new combined therapy. Thus, if to compare with patients treated with traditional therapy, in group I the recurrence rate decreased only up to 49%; in group II - up to 25.8% while in group III - up to 11.4%. Moreover, AGC recurrences in group III were much less pronounced both clinically and immunologically. Conclusion: An innovative approach applied in group III in the form of a combined pharmacolaser therapy course which included antiviral preparations has shown much better results in treating girls with AGC as compared to traditional treatment. It may be explained by more complete correction of immunodeficiency shifts typical for AGC. So, the discussed technique may be a targeted method of choice. The proposed technique is medically safe, stable, with good rehabilitation results; it has no side effects too. Besides, the obtained effect lasts for a long time. One can also see a sharp reduction in the recurrence incidence. All the mentioned advantages allow to implement the discussed new technique widely in gynecological and pediatric practices.

кондиломы аногенитальной области, низкоинтенсивная лазерная терапия, противовирусное лечение, anogenital warts, low-level laser therapy, antiviral treatment

1. Башмакова М.А., Савичева А.М. Папилломавирусная инфекция: Пособие для врачей МЗ РФ. - М., 2003. - 26 с.

2. Богатырева И.И. Современные подходы к лечению папилломавирусной инфекции урогенитального тракта // Лечащий врач. - 2004. - № 3. - С. 35-37.

3. Бычкова О.С. Этапная комбинированная терапия детей и подростков с папилломавирусной инфекцией аногенитальной области: Автореф. дис.. канд. мед. наук. - М., 2010. - 27 с.

4. Грищук А.Ю. Комплексная оценка цитокиновой и функциональной активности фагоцитов у беременных с вирусной инфекцией: Автореф. дис.. канд. мед наук. - М., 2007. - 23 с.

5. Киселев В.И., Киселев О.И. Этиологическая роль вируса папилломы человека в развитии рака шейки матки: генетические и патогенетические механизмы // Цитокины и воспаление. -2003. - Т. 2. - № 4. - С. 31-38.

6. Козырева О.В. Комплексное лечение больных рецидивирующим генитальным герпесом на основании исследования цитокинов на системном и локальном уровнях: Автореф. дис.. канд. мед наук. - М., 2007. - 22 с.

7. Роговская С.И. Папилломавирусная инфекция гениталий: роль интерферонов в патогенезе и лечении // Consilium medicum. - 2003. - Т. 5. - № 5. - Р. 46-47.

8. Хансон К.П., Имянитов Е.Н. Современные представления о канцерогенезе рака шейки матки // Практическая онкология. -2002. - Т. 3. - № 3. - С. 145-155.

9. Aldahan A.S., Mlacker S., Shah V.V., Kamath P., Alsaidan M., Samarkandy S., Nouri K. Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature // Dermatol. Ther. - 2016 May. - 29 (3). - Р. 197-207.

10. Cogrel O. Destructive procedures for genital warts // Ann. Dermatol. Venereol. - 2016 Nov. - 143 (11). - Р. 793-795.

11. Gibbs N.F. Anogenital papillomavirus infections // Curr. Opin. Pediatr. - 1998 Aug. - 10 (4). - Р. 393-397.

12. Holly E.A. Cervical intraepithelial neoplasia, cervical cancer, and HPV // Annual Review of Public Health. - 1996. - 17. - Р. 69-84.

13. Lacey C.J., Woodhall S.C., Wikstrom A., Ross J. 2012 European guideline for the management of anogenital warts // J. Eur. Acad. Dermatol. Venereol. - 2013. - 27. - Р. e263-70.

14. Riethmuller D., Schaal J.P., Mougin C. Epidemiology and natural history of genital infection by human papillomavirus // Gynecol. Obstet. Fertil. - 2002 Feb. - 30 (2). - Р. 139-46.

15. Thurgar E., Barton S., Karner C., Edwards S.J. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation // Health Technol Assess. - 2016 Mar. - 20 (24). - v-vi, 1-486. doi: 10.3310/hta20240.

16. Ylitalo N., Sorensen P., Josefsson A.M. et al. Persistently high loads of human papillomavirus 16 over time were associated with an increased risk for cervical cancer // Lancet. - 2000. - 355. -Р. 2194-2198.